Cerus Corporation

Add links
From Wikipedia, the free encyclopedia

Cerus Corporation
Nasdaq: CERS
IndustryBiotechnology
FoundedSeptember 1991; 32 years ago (September 1991)
as Cerus Technologies Inc[1]
HeadquartersConcord, California, United States
Key people
President and CEO William 'Obi' M. Greenman
ProductsBlood transfusion products
RevenueIncrease $74.649 million (2019)[2]
Number of employees
254 (2019)[3]
Websitewww.cerus.com

Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry.

History[edit]

In the mid-1980s, hematologist Laurence Corash developed a novel method of inactivating HIV particles contained in donated blood plasma using ultraviolet lights. He continued building prototypes with help from colleagues at the UC-San Francisco School of Medicine, and together with chemist John E. Hearst founded the company as Cerus Technologies Inc. on September 19, 1991, later to be renamed as Cerus Corporation in its initial 1996 SEC filing.[1][4][5][6][3][7][8][9]

Products[edit]

The company's proprietary technology (called Helinx) was conceived by Corash in the mid-1980s as a method to protect patients from HIV-tainted plasma and platelet donations in the growing AIDS epidemic. These two blood components were found to be suitable to treat in ex-vivo isolation with the company's UV-A light process due to their naturally translucent properties. The UV exposure process works by intentionally damaging DNA and RNA material in foreign virus and bacteria that might be present, while remaining harmless to the donated blood plasma and platelets (which contains no RNA or DNA).[6][10][11][12][13][14][15][16]

In December 2001, the Helinx process was incorporated into a medical device called Intercept Platelet blood screening system, and Cerus entered an agreement with Baxter International Inc to jointly commercialize the device in the European Union healthcare market and gain regulatory approvals. In 2006, Cerus announced they had acquired all of Baxter's shared commercial rights to the Intercept blood system for plasma and platelets, and also revealed that they were working on expanding their system to treat red blood cells (which are more opaque and harder to treat). Cerus later entered into another commercialization agreement with Grifols S.A. to market and operate their products in blood centers in Spain and Portugal.[17][10][13][18][19]

Regulatory approvals[edit]

The Intercept Blood System for Platelets received EU CE MARK Class III certification in 2002, and US FDA pre-market approval on December 18, 2014. On March 10, 2016 the FDA granted an expanded modification on the existing approval to also treat platelets suspended in 100% plasma. In 2005 the platelet CE MARK was re-approved with a modification to extend platelet storage to seven days (previously five days).[20][10][11][21][22][23][24]

The Intercept Blood System for Plasma received EU CE MARK certification on November 21, 2006, and US FDA pre-market approval on December 16, 2014. Cerus also received certification under ISO 13485 for their blood plasma and platelet products in 2006.[16][25]

On August 23, 2020, Cerus received US FDA Emergency Use Authorization to treat the donated convalescent plasma from recovered COVID-19 patients, with the purpose of giving investigative antibody immunotherapy transfusions to other COVID-19 patients suffering an infection.[26][citation needed]

Effectiveness[edit]

The product's primary purpose is to guarantee a clean supply of blood products, and deactivate both known and unknown pathogens with minimal added effort. The Helinx technology and INTERCEPT system have been shown effective on several types of viruses, but it is not universally effective due to some kinds of pathogens' RNA or DNA being more resilient to the process (such as hepatitis A, human parvovirus 19 and some bacterial spores). Studies have shown the system to be effective at neutralizing HIV, hepatitis B, hepatitis C, West Nile virus, SARS-1 COV, MERS CoV, Zika, dengue fever, and SARS-CoV-19. It is also touted as being able to render certain bacteria[citation needed] unable to replicate.[10][11][27][16]

In addition to pathogen neutralization, there are clinical trials in West Africa to test the effectiveness of using the INTERCEPT system to treat convalescent plasma from Ebola survivors, and administering the treated plasma to other patients still fighting an infection. Convalescent treatments using INTERCEPT are also being applied to Ebola survivor plasma donations at Emory University, and platelet donations in Puerto Rico, which has dengue fever and chikungunya infections in their population. Similarly, the US FDA has granted emergency use of INTERCEPT to sterilize convalescent COVID-19 patient plasma, although the US medical community harbors some disagreements on whether this approach will provide effective relief for its patients.[16]

Market reception[edit]

The Intercept systems are in use in multiple EU healthcare settings. However, the US market had not gained traction among blood centers, due to its added costs on top of an ample domestic supply of pre-screened clean blood, plasma and platelet units.[12][16] In developing countries with lower levels of health care access, the product is finding greater clinical and humanitarian trial opportunities due to high rates of collecting and using unsafe donated whole blood, low access to plasma and platelet separating equipment, and low supply of screening tests.[10][16]

In 2016 during the height of the Zika virus spread, Cerus' technology was supplied to a designated blood center in Rio de Janeiro, Brazil for use in ensuring a clean blood supply for competing athletes in the 2016 Rio Olympic Games.[28]

References[edit]

  1. ^ a b "SEC 10-K Filing archive 2015 for Cerus". Security Exchange Commission. March 16, 2015. Archived from the original on June 25, 2017. Retrieved October 15, 2020.
  2. ^ "Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results". Business Wire. February 20, 2020. Archived from the original on October 17, 2020. Retrieved October 15, 2020.
  3. ^ a b "Cerus Corp - Company Profile and News - Bloomberg Markets". Bloomberg.com. October 15, 2020. Archived from the original on August 18, 2020. Retrieved October 15, 2020.
  4. ^ "About Dr. Laurence M. Corash, Hematologist in San Francisco, CA". US News. October 15, 2020. Retrieved October 15, 2020.
  5. ^ "Biography for Dr. Laurence M Corash MD. San Francisco, CA". Vitals.com. October 12, 2020. Archived from the original on November 19, 2017. Retrieved October 15, 2020.
  6. ^ a b "Concord Biotech Company Cerus Donates Blood Sterilization Tech to Rio Ahead of Olympic Games". NBC Bay Area News. July 20, 2016. Archived from the original on September 28, 2016. Retrieved October 15, 2020.
  7. ^ "Cerus Corp. CERS - Quotes, Financials, News, Charts and Research - US News Best Stocks". U.S. News. October 15, 2020. Archived from the original on October 17, 2020. Retrieved October 15, 2020.
  8. ^ "SEC S-1 Filing registration 1996 for Cerus Corporation". Security Exchange Commission. September 4, 1996. Archived from the original on October 17, 2020. Retrieved October 15, 2020.
  9. ^ "John E. Hearst, Ph.D., Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who". Marquis Who's Who, via 24-7PressRelease. October 30, 2018. Archived from the original on November 7, 2018. Retrieved October 15, 2020.
  10. ^ a b c d e Nkohkwo, Asa’ah; Agbor, Gabriel; Asongalem, Emmanuel; Tagny, Claude; Asonganyi, Tazoacha (June 9, 2016). "Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion". African Journal of Laboratory Medicine. 5 (1): 363. doi:10.4102/ajlm.v5i1.363. ISSN 2225-2002. PMC 5436399. PMID 28879109.
  11. ^ a b c Schlenke, Peter (2014). "Pathogen Inactivation Technologies for Cellular Blood Components: an Update". Transfusion Medicine and Hemotherapy. 41 (4): 309–325. doi:10.1159/000365646. ISSN 1660-3796. PMC 4164100. PMID 25254027.
  12. ^ a b Picker, Susanne M. (March 13, 2013). "Current methods for the reduction of blood-borne pathogens: a comprehensive literature review". Blood Transfusion. 11 (3): 343–348. doi:10.2450/2013.0218-12. ISSN 1723-2007. PMC 3729123. PMID 23522896.
  13. ^ a b "New procedure could help protect U.S. blood supply". The Tuscaloosa News. Associated Press. June 5, 2001. p. 2A. Retrieved October 15, 2020 – via Google.com.
  14. ^ Neergaard, Lauran (October 1, 2002). "Testing marks first step toward sterilizing blood". Gettysburg Times. Associated Press. p. A5. Retrieved October 15, 2020 – via Google.com.
  15. ^ "Package Insert - INTERCEPT® Blood System for Plasma" (PDF). Cerus Corporation. February 10, 2015. Archived from the original on October 17, 2020. Retrieved October 15, 2020.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  16. ^ a b c d e f "F.D.A. Approves System That May Make Blood Transfusions Safer". The New York Times. December 16, 2014. Archived from the original on December 17, 2014. Retrieved October 15, 2020.
  17. ^ "Health care giant Baxter to license blood screeing system". Memphis Business Journal. December 10, 2001. Archived from the original on July 11, 2004. Retrieved October 15, 2020.
  18. ^ "Cerus Obtains Exclusive Rights to INTERCEPT Blood System from Baxter". DotMed Healthcare Business News. February 14, 2006. Archived from the original on February 1, 2012. Retrieved October 15, 2020.
  19. ^ "Grifols And Cerus Agree To Commercialize INTERCEPT Blood System In Spain And Portugal". Med Device Online. July 24, 2007. Archived from the original on October 17, 2020. Retrieved October 15, 2020.
  20. ^ "INTERCEPT Blood System Received TÜV Approval for Storage of Platelets up to 7 Days". OTS.at. Archived from the original on October 17, 2020. Retrieved October 17, 2020.
  21. ^ "Baxter and Cerus Reach Agreement with FDA on Steps to Gain Regulatory Approval for Innovative Pathogen Inactivation System". Infection Control Today. Retrieved October 17, 2020.
  22. ^ "Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59". BioDrugs. 17 (1): 66–68. 2003. doi:10.2165/00063030-200317010-00006. ISSN 1173-8804. PMID 12534321. Archived from the original on October 17, 2020. Retrieved October 17, 2020.
  23. ^ "FDA Approval Letter – INTERCEPT Blood System for Platelets". USFDA. December 18, 2014. Archived from the original on October 17, 2020. Retrieved October 15, 2020.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  24. ^ "FDA Approval Letter – Supplement to INTERCEPT Blood System for Platelets" (PDF). USFDA. March 10, 2016. Archived from the original on October 17, 2020. Retrieved October 15, 2020.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  25. ^ "FDA Approval Letter – INTERCEPT Blood System for Plasma". USFDA. December 16, 2014. Archived from the original on October 17, 2020. Retrieved October 15, 2020.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  26. ^ Commissioner, Office of the (August 24, 2020). "FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration's Fight Against Pandemic". FDA. Retrieved April 26, 2022.
  27. ^ Hashem, A. M.; Hassan, A. M.; Tolah, A. M.; Alsaadi, M. A.; Abunada, Q.; Damanhouri, G. A.; El‐Kafrawy, S. A.; Picard‐Maureau, M.; Azhar, E. I.; Hindawi, S. I. (November 6, 2019). "Amotosalen and ultraviolet A light efficiently inactivate MERS‐coronavirus in human platelet concentrates". Transfusion Medicine (Oxford, England). 29 (6): 434–441. doi:10.1111/tme.12638. ISSN 0958-7578. PMC 7169717. PMID 31696565.
  28. ^ "Concord's Cerus helps ensure blood safety for Rio Olympics". San Francisco Chronicle. July 13, 2016. Archived from the original on July 19, 2020. Retrieved October 15, 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cerus_Corporation&oldid=1189660874"